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Background. Chronic renal disease substantially increases
the risk of cardiovascular events and death. Vasopeptidase in-
hibitors are known to show a strong antihypertensive effect.
In the present study, we investigated the nephroprotective po-
tential of the vasopeptidase inhibitor AVE7688 beyond its an-
tihypertensive effects in a mouse model of progressive renal
fibrosis.
Methods. COL4A3 −/− mice received 25 mg AVE7688 per
kg body weight. Treatment was initiated in week 4 (early) and
week 7 (late). Eight mice per group were sacrificed after 7.5 or
9.5 weeks, and serum levels of urea, systemic blood pressure, and
proteinuria were measured. Renal tissue was investigated by
routine histology, electron microscopy, immunohistochemistry,
and Western blotting. Lifespan until death from renal fibrosis
was monitored.
Results. Lifespan of treated mice increased by 143% (early
therapy) and by 53% (late therapy) compared to untreated ani-
mals (172 ± 19 vs. 109 ± 15 vs. 71 ± 6 days, P < 0.01). Untreated
COL4A3 −/− mice did not develop severe hypertension (mean
systolic blood pressure 116 ± 14 vs. 111 ± 9 mm Hg in wild-
type mice), and both therapies mildly reduced systemic blood
pressure (107 ± 13 and 105 ± 14 mm Hg, data not significant).
AVE7688 decreased proteinuria from 12 ± 3 g/L in untreated
mice to 2 ± 1 g/L (early) and to 4 ± 1 g/L (late therapy, P < 0.05),
as well as serum-urea from 247 ± 27 to 57 ± 10 and to 105 ±
20 mmol/L (P < 0.05). Extent of fibrosis, inflammation, and
profibrotic cytokines was reduced by AVE7688 therapy.
Conclusion. The results indicate a strong nephroprotective
effect of the vasopeptidase inhibitor in this animal model of
progressive renal fibrosis. Besides the antihypertensive action
of AVE7688, its antifibrotic, anti-inflammatory, and antiprotein-
uric effects demonstrated in the present study may serve as an
important therapeutic option for chronic inflammatory and fi-
brotic diseases in man.
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Chronic renal disease substantially increases the risk
of cardiovascular events and death [1]. The common end
point of most chronic renal diseases, such as chronic
glomerulonephritis and diabetic nephropathy, is renal fi-
brosis. Tissue damage in chronic glomerulonephritis, for
example, is related to the individual immune response,
leading to excessive inflammation, failure to activate
regression and glomerular repair, and excessive fibro-
genic activity. Therefore, therapy of chronic renal dis-
eases needs to target acute and chronic inflammation, as
well as progressive renal fibrosis. At present, standard
therapeutic regimens include pharmacologic blockade of
the renin-angiotensin-aldosterone system by either inhi-
bition of angiotensin-converting enzyme (ACE) or block-
ade of the angiotensin II receptor. Both therapies have
been shown to delay progression of chronic renal dis-
eases such as diabetic nephropathy and chronic glomeru-
lonephritis [2–4]. However, despite some success of these
therapies, chronic progressive renal disease continues to
present a therapeutic challenge because the prevalence of
patients on chronic renal replacement therapy increases
by 5% to 7% per year in the United States and Europe.
The limitations of current therapies stimulate research
in this field and the development of new treatment op-
tions [5]. One strategy that received considerable atten-
tion is the development of vasopeptidase inhibitors [6, 7].
These drugs simultaneously inhibit the activity of ACE
and neutral endopeptidase (NEP). NEP is an endothe-
lial cell surface zinc metallopeptidase. It is the major en-
zymatic pathway of degradation of natriuretic peptides,
and a secondary enzymatic pathway for degradation of
kinins [8]. Vasopeptidase inhibitors were developed in
an effort to generate superior effects compared to pure
ACE inhibitors; however, their therapeutic value in renal
end-organ damage has not yet been fully explored [9].
The vasopeptidase inhibitor omapatrilat has shown po-
tent organ protection in models of salt-induced hyper-
tension [10, 11], and in a hypertensive, hypoinsulinemic
nephropathy model [12]. However, the potential ben-
efit of pharmacologic intervention by vasopeptidase
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inhibition in chronic progressive fibrotic renal diseases
irrespective from its antihypertensive effects has not yet
been evaluated.
In the present study, we investigated whether preemp-
tive or late treatment with the novel vasopeptidase in-
hibitor AVE7688 has nephroprotective antifibrotic or
anti-inflammatory effects in COL4A3 −/− mice. The
COL4A3 −/− mice are a nonhypertensive animal model
of progressive renal fibrosis [13–16], similar to the hu-
man Alport syndrome (AS) [13, 14]. AS is a hereditary
nephropathy characterized by progressive renal failure,
sensorineural deafness, and typical ocular changes [17].
The disease in mice and humans is caused by mutations
in type IV collagen genes, leading to an abnormal com-
position of the glomerular basement membrane (GBM).
Previous studies demonstrated that abnormal composi-
tion of the GBM leads to secondary events, resulting in
renal fibrosis [13–15]. Important end points of the present
study with AVE7688 included lifespan until death from
progressive renal failure of treated mice versus untreated
mice, systemic blood pressure, proteinuria, renal func-
tion, glomerular and tubulointerstitial fibrosis, inflamma-
tion, and profibrotic cytokines.
METHODS
Animals
Genotyping of COL4A3 −/− mice (Jackson Lab, Bar
Harbor, ME, USA) was carried out by polymerase chain
reaction (PCR) as described before [13, 14]. Treatment
protocols for the mice were previously approved by lo-
cal German authorities and supervised by veterinarians.
Mice were bred on a 129/SvJ genetic background in a
pathogen-free environment.
Experiments
Systolic arterial blood pressure was measured using
a noninvasive pressure cuff system (LE5001, Panlab,
Barcelona, Spain). Ten microliters of urine were used for
microelectrophoresis on a gradient polyacrylamide gel, a
semiquantitative technique used to qualify and quantify
proteinuria [14, 15, 18]. Gels were stained by coomassie
blue and analyzed by densitometry. Serum urea levels
were analyzed on a Hitachi 917 Automatic Analyzer
(Boehringer Mannheim, Mannheim, Germany).
AVE7688 was mixed into pallets of standard Western
diet at a concentration of 125 parts per million accord-
ing to recommendations by the manufacturer (Aventis
GmbH, Bad Soden, Germany). Food intake was mea-
sured in metabolic cages to ensure constant drug intake.
Wild-type mice served as control animals. Eighty-four ho-
mozygous COL4A3 −/− mice were divided into 3 groups:
(1) untreated animals (total N = 40; N = 24 survival; N =
8 sacrificed in week 7.5; N = 8 sacrificed in week 9.5); (2)
early AVE7688 therapy, starting at week 4 before onset
of proteinuria (total N = 26; N = 10 survival; N = 8 sac-
rificed in week 7.5; N = 8 sacrificed in week 9.5); (3) late
AVE7688 therapy, starting at week 7 after onset of pro-
teinuria (total N = 18; N = 10 survival; N = 8 sacrificed
in week 9.5).
Light and electron microscopy
Eight animals per group were sacrificed at week 7.5,
and 8 at week 9.5. Three mice per group were per-
fused transcardially, and kidneys were immersion-fixed
for electron microscopy as described before [14]. Sec-
tions were taken on a Reichert Ultracut UCT ultramicro-
tome. A Zeiss Axiophot microscope (Zeiss, Go¨ttingen,
Germany) and a Zeiss EM 902 microscope were used
for histologic documentation. For paraffin sections, kid-
neys were fixed as described before [14]. Sections
were incubated overnight with primary antibodies rab-
bit anti-EHS-laminin (gift from M. Paulsson, Cologne,
Germany), goat antifibronectin (St. Cruz, Heidel-
berg, Germany), and POX-conjugated mouse anti-a-
smooth musle actin (Dako, Hamburg, Germany). As
negative control, slides were incubated with control
immunoglobulin. Subsequently, cy3-labeled secondary
antibodies (Jackson ImmunoReagents, West Grove, PA,
USA) were added for 1 hour. Immunohistochemistry
for CD3-positive T cells (rat anti-CD3; Serotec, Raleigh,
NC, USA) and F4/80 positive monocytes/macrophages
(rat anti-F4/80, Serotec, Raleigh, NC) was performed
as previously described [19]. Endogenous peroxidase
was blocked, and antigen retrieval was performed ei-
ther in Antigen Retrieval Solution (Vector, Burlingame,
CA, USA) by autoclaving (for CD3), or by pro-
teinase K digestion (for F4/80). The Avidin/Biotin
blocking Kit (Vector) was used to block endogeneous
biotin before incubation with the primary antibod-
ies. This was followed by incubation with a biotiny-
lated antirat IgG antibody (Vector), and the ABC
reagent (Vector). 3′3′Diaminobenzidine (DAB; Sigma,
Taufkirchen, Germany) with metal enhancement (re-
sulting in a black color product) served as detection
system. Slides were counterstained with methyl green,
dehydrated, and mounted.
Immunoblot
Thirty lg protein aliquots [as shown by BCA pro-
tein assay (Pierce, Rockford, IL, USA)] of tissue ex-
tracts from kidneys of untreated animals in week 7.5
and 9.5, and from kidneys of treated animals in week
7.5 and 9.5 were dissolved in sodium dodecyl sulfate
(SDS) sample buffer, separated by electrophoresis in a
15% SDS-polyacrylamide gel, transferred to nitrocellu-
lose membrane, and blocked. Mouse anti-TGFb1 (R&D
Systems, Minneapolis, MN, USA) and rabbit anti-CTGF
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Fig. 1. Nephroprotective effect on renal failure (lifespan) in treated
animals. Box-plot analysis: lifespan until death from renal failure in-
creased significantly by early treatment from 70.9 ± 6.0 to 172 ± 19 days
(P < 0.001). When therapy was initiated after onset of proteinuria (late
therapy), animals lived to 109 ± 15 days (P < 0.01).
(Abcam Limited, Cambridge, United Kingdom) were
incubated for 60 minutes. The membrane was then
incubated with secondary antibody conjugated with
horseradish peroxidase (HRP; Dako), and the blot was
developed using chemiluminescence. Protein-expression
was analyzed densitometrically using a gel-pro analyzer
software (Media Cybernetics, San Diego, CA, USA).
Each immunoblot was repeated 3 times.
Statistics
Data are presented as mean ± SEM. Data were ana-
lyzed by log-rank statistic (survival analysis) and two-way
analysis of variance (ANOVA).
RESULTS
AVE7688 extends lifespan of COL4A3 −/− mice
Lifespan was continuously documented over a 12-
month period (Fig. 1). No animals were lost due to in-
fections or adverse effects of therapy. No signs of severe
hypertension such as heart hypertrophy, increased sep-
tum size, or media sclerosis were found in any animals.
Lifespan of 24 untreated COL4A3 −/− mice was 70.9 ±
6.0 days. Life expectancy of mice in group II (early ther-
apy; N = 10) increased by 143% to 172 ± 19 days (P <
0.001). Lifespan of mice in group III (late therapy; N =
10) increased by 53% to 109 ± 15 days (P < 0.01). The
Table 1. Antihypertensive effect of AVE7688
Wild-type Homozygous Homozygous Homozygous
placebo placebo late therapy early therapy
9.5 weeks 111 ± 9 116 ± 14 105 ± 13 107 ± 14
12 weeks 113 ± 11 animals dead 111 ± 16 114 ± 12
N = 5 N = 5 N = 4 N = 4
Systolic mean arterial blood pressure (mm Hg) of COL4A3 −/− mice with
and without medical treatment.
difference between early and late treatment was highly
significant (P < 0.001).
Both therapeutic regimens decrease systolic blood
pressure and reduce proteinuria
Mean systolic blood pressure was moderately in-
creased in untreated COL4A3 −/− compared to wild-
type control animals in week 9.5; however, differences
were not significant in Student t test (Table 1). Both ther-
apeutic regimens slightly reduced blood pressure in week
9.5 and 12 (data not significant). No differences in sys-
temic blood pressure were found between the early and
late treatment group.
Early therapy reduced proteinuria from 5 g/L in un-
treated animals to less than 1 g/L in week 7.5, and from
12 g/L to 2 g/L in week 9.5; late therapy reduced protein-
uria to 4 g/L in week 9.5 (P < 0.05; Fig. 2). Reduction of
proteinuria was more than 50% in both therapeutic reg-
imens, with no significant differences between early and
late treatment group after week 9.5.
Both therapies delay onset of uremia; however, deterio-
ration of renal function is significantly slower in the early
therapy group compared to late therapy after onset of pro-
teinuria. In untreated mice (N = 6), serum urea started
to rise above 50 mg/dL at week 7.5 and to 247 ± 27 mg/dL
by week 9.5, followed by death soon after. In early treated
mice (N = 6), deviation of urea was delayed by 4 weeks.
By week 12, urea of early treated mice rose to 67 ± 11
mg/dL; in contrast, urea of late treated mice (N = 6) was
significantly higher (153 ± 21; P < 0.05).
Early and late AVE7688 therapy reduces abnormal
deposition of the renal extracellular matrix, as well as
numbers of activated fibroblasts, T lymphocytes, and
macrophages. Electron microscopy of COL4A3 −/−
mice showed characteristic thickening and splitting of the
GBM in untreated animals (Fig. 4E). Abnormal intracel-
lular amounts of fibrillar collagens, and a complete loss of
the podocyte foot processes in untreated animals, could
also be observed (Fig. 4E). These changes appeared to
be improved by early AVE7688 therapy (Fig. 4I) because
intact foot processes and slit membranes could still be
found.
Light microscopy demonstrated early periglomerular
fibrosis in untreated mice by week 7.5 (Fig. 4F), leading
to complete loss of glomerular function and nephrons
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Fig. 2. Antiproteinuric effect of AVE7688 in
COL4A3 −/− mice. Each dot represents the
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Fig. 3. Nephroprotective effect of AVE7688 on renal function. Levels
of serum urea were measured every other week. Each dot represents
the average amount of serum-urea of 6 different animals. ∗P < 0.05
(compared to healthy control animals).
paralleled by severe glomerular and tubulointerstitial fi-
brosis in week 9.5 (Figs. 4G and H). Fibrotic changes
of the glomerulum, as well as of the tubulointerstitium,
were less severe in the early therapy group in week 7.5
(Fig. 4J). In these animals, a preserved glomerular archi-
tecture without apparent tubulointerstitial fibrosis could
be noted in week 9.5 (Figs. 4K and L), with only mild
mesangial expansion (Fig. 4K).
Immunohistochemistry confirmed these changes
(Fig. 5): wild-type mice showed scant staining for
fibronectin (Fig. 5A). Fibronectin staining was increased
in the periglomerular matrix of untreated COL4A3 −/−,
a typical finding of severe glomerulosclerosis (Fig. 5B).
Compared to untreated COL4A3 −/− mice, staining was
reduced in early treated animals (Fig. 5D), as well as in
animals treated after onset of proteinuria (late therapy)
(Fig. 5C), both treatment groups showed only a mild
staining of the periglomerular matrix.
Healthy control animals showed a thin tubular and
glomerular basement membrane (EHS-laminin; Fig. 5E
and I). In contrast, increased matrix deposition was seen
in untreated animals (Fig. 5F and J), laminin staining be-
ing present in the intra- and periglomerular, as well as in
intertubular regions. Localized shrinkage of tubular lu-
men was also noted, indicating loss of function of differ-
ent nephrons. Periglomerular and intertubular signal was
decreased in the early therapy group, with almost normal
staining in the intertubular space and a preserved tubu-
lar lumen, suggesting preserved function of nephrons
(Fig. 5G and K). Signalling was more prominent and,
again, no loss of nephrons was found in the late ther-
apy group (Fig. 5H and L), indicating that late therapy
after onset of proteinuria prevented periglomerular and
tubulointerstitial fibrosis, as well.
The anti-inflammatory potential of AVE7688 therapy
was investigated by immunostaining for T lymphocytes
(Fig. 6A to D), macrophages (Fig. 6E to H), and ac-
tivated fibroblasts (Fig. 6I to L): compared to wild-
type control animals (Fig. 6A), untreated COL4A3 −/−
showed a glomerular, periglomerular, and tubulointer-
stitial signal for CD3-positive cells (T-lymphocytes, Fig.
6B). This signalling was reduced by late (Fig. 6C) and
early therapy (Fig. 6D). Untreated COL4A3 −/− mice
also showed a periglomerular and tubulointerstitial signal
for F4/80-positive cells (macrophages, Fig. 6F, wild-type
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A B C D
E F G H
I J K L Fig. 4. Nephroprotective effect of AVE7688
therapy on renal architecture. Representative
figures from wild-type control animals (up-
per row, A to D), untreated (middle row, E
to H), and AVE7688 early treated COL4A3
−/− mice (lower row, I to L). A, B, E, F, I, and
J: all mice 7.5 weeks of age; C, D, G, H, K, and
L: all mice 9.5 weeks of age. Original magnifi-
cation, left row: 20,000- to 30,000-fold; middle
row: 1000-fold; right row: 400- to 600-fold. C,
capillary lumen; P, podocytes and podocytes’
foot processes.
A B C D
E F G H
I J K L Fig. 5. Antifibrotic effect of AVE7688 ther-apy. Immunostaining for fibronectin and
EHS-laminin. Representative figures from
wild-type control animals (left, A, E, and I),
untreated (B, F, and J), early treated (C, G,
and K), and late treated COL4A3 −/− mice
(D, H, and L). All mice 9.5 weeks of age. Orig-
inal magnification, upper row: 400-fold; mid-
dle row: 100-fold; lower row: 800-fold.
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Fig. 6. Anti-inflammatory effect of AVE7688
therapy. Immunostaining for T lymphocytes
(upper row), activated macrophages (middle
row), and fibroblasts (lower row). Represen-
tative figures from wild-type control (A, E,
and I), untreated (B, F, and J), late treated
(C, G, and K), and early treated COL4A3 −/−
mice (D, H, and L). All mice 9.5 weeks of age.
Original magnification, 100- and 400-fold.
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CTGF
Fig. 7. Antifibrotic effect of AVE7688 ther-
apy. Immunoblot for TGFb and CTGF. IOD,
integrated optical density; N, number of ani-
mals pooled.
control, Fig. 6E). Again, this signalling was reduced by
late (Fig. 6G) and early therapy (Fig. 6H). Similar results
were found by staining for a-smooth muscle actin (acti-
vated fibroblasts, wild-type control, Fig. 6I). Untreated
COL4A3 −/− mice showed a periglomerular and tubu-
lointerstitial signal (Fig. 6J) that was reduced by late and
early AVE7688 therapy (Fig. 6K and L).
For further analysis, glomeruli of 3 different animals
of each group were evaluated for glomerulosclerosis in
week 9.5 by a blinded observer. Glomeruloscerosis was
defined as loss of more than 50% of glomerular lumen
due to extracellular matrix accumulation. Two out of
94 (2.1%) glomeruli of healthy control animals showed
sclerosis, whereas 78 out of 87 (89.7%) did in untreated
COL4A3 −/−. In contrast, only 12 out of 92 (13.0%) of
glomeruli of early AVE7688-treated COL4A3 −/−, and
28 out of 88 (31.8%) of glomeruli of late-treated animals
showed sclerosis. Tubulointerstitial fibrosis was evaluated
in a similar matter by grading 12 different kidney sec-
tions of 3 animals per experimental group (total of 36
sections) into zero, 1+, and 2+ accumulation of extracel-
lular matrix by a blinded observer. Healthy control ani-
mals showed no accumulation of extracellular matrix in
any section (matrix score 0.0); untreated COL4A3 −/−
showed an average matrix score of 1.86. Early treated
mice showed a matrix score of 0.47, late treated mice of
0.81.
AVE7688 therapy strongly reduces TGFb1 and CTGF
protein expression in this model of progressive renal fi-
brosis. We speculated that the nephroprotective effect
of AVE7688 in the COL4A3 −/− mice may be due to
down-regulation of the profibrotic cytokines TGFb and
CTGF (Fig. 7). Compared to untreated mice in week 7.5
and 9.5 (lanes 5 and 2), early AVE7688 therapy (lanes 6
and 3) resulted in down-regulation of TGFb( by nearly
300% and of CTGF by more than 300%(This effect was
found to be weaker in the late therapy group (lane 1)
(down-regulation of TGFb and CTGF by nearly 50%).
DISCUSSION
COL4A3 −/− mice with Alport syndrome serve as
a model of progressive renal disease, leading to renal
fibrosis and end-stage renal failure [16]. All untreated
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animals showed a similar onset of uremia and proteinuria,
resulting in death by 10 weeks of age. These changes al-
lowed observation of the antifibrotic, anti-inflammatory
nephroprotective potential of the novel vasopeptidase in-
hibitor AVE7688. The drug was given before onset of pro-
teinuria (early therapy, mimicking the clinical setting of
a prophylactic nephroprotective therapy in patients with
microalbuminuria), or after onset of proteinuria above
3 g/L (late therapy, mimicking the clinical setting of a
nephroprotective therapy in patients with nephrotic syn-
drome and ongoing renal insufficiency). A nephropro-
tective effect of both therapeutic regimens was clearly
demonstrated: lifespan—the most evident end point—
was prolonged by 143% in the early therapy group and
by 53% in the late therapy group. A significantly greater
effect on lifespan was demonstrated when therapy started
early as compared to the late therapy.
The antihypertensive effect of AVE7688 (Table 1) in
our non- or only mild-hypertensive animal model with Al-
port disease [20] was mild, and not significantly different
to treatment with an AT1 antagonist that showed similar
antihypertensive, but a weaker nephroprotective, antifi-
brotic potential than AVE7688 in the same mouse model
in a previous study [15]. Therefore, the strong nephro-
protective effect of AVE7688 cannot be explained by its
antihypertensive effects alone.
Urinary proteins have been shown to induce progres-
sive interstitial fibrosis, and the known antiproteinuric
effects of ACE inhibitors and AT1 antagonists have been
suggested to be nephroprotective [21–23]. Our study
demonstrated a strong antiproteinuric effect of early and
late AVE7688 therapy that may well have contributed to
renoprotection in this model. Both therapeutic regimens
showed a comparable antiproteinuric potential. How-
ever, early therapy was significantly more effective in pro-
longing lifespan; therefore, the better nephroprotective
effect of early AVE7688 therapy might be explained by
additional nephroprotective mechanisms beyond its an-
tiproteinuric and antihypertensive action.
ACE inhibitors have been shown to be effective in pre-
serving renal function in several human renal diseases
[2–4, 21–23]. ACE inhibitors block the conversion of an-
giotensin I to angiotensin II, a growth factor which acti-
vates fibroblasts, leading to increased synthesis of matrix
proteins [24]. Angiotensin II is also a profibrotic cytokine,
activating mononuclear cells and increasing proinflam-
matory mediators [24], as well as regulating matrix degra-
dation. Some of the downstream effects of angiotensin II
are mediated directly via the TGFb pathway, which has
been shown to be important in the pathogenesis of renal
fibrosis and inflammatory cell infiltration such as mono-
cytes in AS [13–15, 25, 32]. Our data show that levels
of TGFb and CTGF are increased in untreated COL4A3
−/− (Fig. 7). Early therapy with AVE7688 reduced TGFb
and CTGF expression more efficiently than late ther-
apy did. This was paralleled by the preservation of renal
function. These results emphasize the role of TGFb and
CTGF in progression of renal fibrosis in the COL4A3
−/− mice.
Angiotensin II plays an important role in chemotaxis of
inflammatory cells such as macrophages and monocytes
and additional proinflammatory effects [26]. Our model
of chronic renal fibrosis is not a primary inflammatory an-
imal model. However, kidneys of untreated mice showed
a profound infiltration of inflammatory cells, such as T
lymphocytes, macrophages, as well as an increased num-
ber of activated fibroblasts. COL4A3 −/− mice treated
with AVE7688 showed an almost complete loss of these
inflammatory infiltrates (Fig. 6), which was superior to
the anti-inflammatory effect of ramipril (data not shown).
Inflammatory cells play a major role in developing tubu-
lointerstitial fibrosis and loss of nephron function, and
have as well been shown to be key participants in the
pathogenesis of renal fibrosis in AS [15, 27] and in most
other chronic renal diseases leading to fibrosis and end-
stage renal failure.
In previous studies with COL4A3 −/− mice, we found
an antifibrotic effect of early therapy with the ACE in-
hibitor ramipril, which prolonged lifespan by 111% [14].
Late therapy with ramipril, however, did not prolong
lifespan in COL4A3 −/− mice. In contrast, late therapy
with AVE7688 prolonged lifespan by 53% (P < 0.01 com-
pared to placebo). The superior nephroprotective poten-
tial of the vasopeptidase inhibitor might be explained by
its anti-inflammatory effects (Fig. 6).
CONCLUSION
Lifespan of Alport mice strongly depended on the time
point when AVE7688 treatment was initiated. AVE7688
might, as well, be able to delay onset of renal failure and
fibrosis in humans with Alport syndrome. We conclude
that therapy with AVE7688 in patients with chronic re-
nal disease might have a profound nephroprotective ef-
fect in regards to reduction of both proinflammatory and
profibrotic factors, being the major players in progres-
sion of chronic renal diseases. The nephroprotective po-
tential of AVE7688 might be most effective in patients
with yet mild chronic renal disease (such as microalbu-
minuria), but might still be profound in patients with
progressed chronic renal disease (such as patients with
nephrotic syndrome or beginning renal failure). Previous
studies showed that vasopeptidase inhibition could pre-
vent diabetic nephropathy [12, 28, 29] and endothelial
dysfunction [11, 30, 31]. According to our data, the novel
vasopeptidase inhibitor AVE7688 might indeed have su-
perior effects over pure ACE inhibitors in regards to pre-
vention and delay of renal end-organ damage due to its
additive antifibrotic and anti-inflammatory potential.
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